Literature DB >> 33229692

Excimer laser phototherapeutic keratectomy with mitomycin C application to treat haze after myopic photorefractive keratectomy.

Priyanka Sudanaboina1, Somasheila I Murthy1, Varsha M Rathi1.   

Abstract

Entities:  

Keywords:  MMC- Mitomycin C; PRK Haze; PRK- Photorefractive keratectomy; PTK- Phototherapeutic keratectomy

Mesh:

Substances:

Year:  2020        PMID: 33229692      PMCID: PMC7856928          DOI: 10.4103/ijo.IJO_1845_20

Source DB:  PubMed          Journal:  Indian J Ophthalmol        ISSN: 0301-4738            Impact factor:   1.848


× No keyword cloud information.
A 30-year-old female patient underwent bilateral photorefractive keratectomy (PRK) with mitomycin C (MMC) application to correct compound myopic astigmatism of -8.50,-0.50@60, and -2.25, 1.00@70 in her right eye (RE) and left eye (LE), respectively. RE pachymetry was 513 μm and the anterior chamber depth was 2.57 mm and hence PRK with MMC application was considered. MMC 0.02% was applied for 90 s in RE and 30 s in LE. At 1 month, uncorrected visual acuity (UCVA) was 20/20 in both eyes. However, at 2 months, her RE UCVA dropped to 20/80. Examination showed dense reticular haze (grade 3)[1] [Fig. 1]. The central corneal thickness was 382 μm in the RE [Fig. 2]. Anterior segment optical coherence tomography (OCT) showed intense hyperreflectivity at the level of the epithelial basement membrane corresponding to the haze and undulation of the anterior edge of this scar tissue [Fig. 3]. After an initial failed course of topical corticosteroids, she underwent phototherapeutic keratectomy (PTK) + PRK 6 months after PRK, using the trans-PTK mode for ablation of 50 μ and PRK for 40 μ ablation and MMC was applied for 30 s. At 3 months post PTK, UCVA was 20/30, (20/20 with-0.50,-0.50@60) [Table 1]. No further regression or increase in the haze was noted 18 months after retreatment.
Figure 1

RE slit-lamp photograph with evident grade 4 haze 6 months after PRK (a), and 3 months after PTK + PRK + MMC (b), the corneal opacity is remarkably reduced

Figure 2

Right eye video keratography maps before (a) and 3 months after (b) PTK + PRK + MMC for treatment of post-PRK haze. The topographic pattern highlights the more regularized corneal profile

Figure 3

ASOCT pictures before (a) and 3 months after PTK + PRK + MMC (b). The hyperreflectivity at basement membrane level (arrow) is reduced in intensity (arrow) post-laser retreatment

Table 1

Temporal changes in visual acuity, refractive correction, and slit-lamp haze grading after sequential PRK and PTK + PRK + MMC procedures

Right eyeUCVABCVASpherical equivalentHaze
Preoperative20/60020/25-9.000
2 months post PRK20/8020/25-1.753
6 months post PRK20/10020/25-2.504
Post PTK + PRK20/3020/20-0.752
RE slit-lamp photograph with evident grade 4 haze 6 months after PRK (a), and 3 months after PTK + PRK + MMC (b), the corneal opacity is remarkably reduced Right eye video keratography maps before (a) and 3 months after (b) PTK + PRK + MMC for treatment of post-PRK haze. The topographic pattern highlights the more regularized corneal profile ASOCT pictures before (a) and 3 months after PTK + PRK + MMC (b). The hyperreflectivity at basement membrane level (arrow) is reduced in intensity (arrow) post-laser retreatment Temporal changes in visual acuity, refractive correction, and slit-lamp haze grading after sequential PRK and PTK + PRK + MMC procedures

Discussion

PRK is a safe surgical procedure for effectively reducing refractive errors but refractive regression and corneal haze are known complications that can affect the outcome.[2] The risk factors for post-PRK haze include higher degrees of myopia and astigmatism, hyperopic corrections, and younger age.[3] The symptoms associated with haze are disabling glare and impairment of visual acuity. Intraoperative MMC use has a protective role. Post-PRK haze can be treated with topical steroids if mild, but in a dense haze, surgical management is required.[4] The various techniques include either manual debridement or PTK and MMC application.[5] Our case had risk factors of high myopia and deeper ablation, which led to haze but could be successfully treated with PTK, PRK, and intraoperative MMC application.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial support and sponsorship

Hyderabad Eye Research Foundation.

Conflicts of interest

There are no conflicts of interest.
  5 in total

1.  Repeated excimer laser treatment after photorefractive keratectomy.

Authors:  T Seiler; M Derse; T Pham
Journal:  Arch Ophthalmol       Date:  1992-09

2.  Corneal Breakthrough Haze After Photorefractive Keratectomy With Mitomycin C: Incidence and Risk Factors.

Authors:  Igor Kaiserman; Naʼava Sadi; Michael Mimouni; Tzahi Sela; Gur Munzer; Shmuel Levartovsky
Journal:  Cornea       Date:  2017-08       Impact factor: 2.651

3.  Excimer laser photorefractive keratectomy for myopia. Clinical results in sighted eyes.

Authors:  B Tengroth; D Epstein; P Fagerholm; H Hamberg-Nyström; T D Fitzsimmons
Journal:  Ophthalmology       Date:  1993-05       Impact factor: 12.079

4.  The correction of high myopia using the excimer laser.

Authors:  J Heitzmann; P S Binder; B S Kassar; L T Nordan
Journal:  Arch Ophthalmol       Date:  1993-12

5.  Risk factors for early-onset corneal haze after photorefractive keratectomy in an Asian population: Outcomes from the Singapore Armed Forces Corneal Refractive Surgery Programme 2006 to 2013.

Authors:  Bryan Chin Hou Ang; Reuben Chao Ming Foo; Edmund Wei Long Lim; Mellisa Mei Hui Tan; Gerard Kwang Ming Nah; Lennard See Yin Thean; Clement Woon Teck Tan; Paul Song Bo Zhao
Journal:  J Cataract Refract Surg       Date:  2016-05       Impact factor: 3.351

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.